

## Case Report

# Evans Syndrome with Acute Kidney Injury

Hanfei Lin, MD<sup>1</sup>; Kefei Wu, MD<sup>1</sup>; Weidai Zhang, MD<sup>1</sup>; Guili Lin, MD<sup>1</sup>; Chudan Cai, MD<sup>1\*</sup><sup>1</sup>Department of Nephrology Medicine, The first Affiliated Hospital of Shantou University Medical College, Shantou, China.**Abstract**

Evans syndrome is a rare syndrome associated with the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP). Furthermore, acute kidney injury (AKI) is a syndrome characterized by the rapid loss of kidney excretory function and is most often secondary to extrarenal events. However, AKI has rarely been recorded in Evans syndrome without systemic autoimmune disease and malignant tumors of the blood and lymphatic system. Herein, we report the case of a patient who exhibited Evans syndrome presenting with AKI.

A 73-year-old woman presented with diarrhea, anuria, low platelet count, and a progressive increase in blood urea nitrogen and serum creatinine as well as anemia with a positive direct Coombs test. We excluded hemolytic uremic syndrome, ITP, and leukemia. Treatment with antibiotics, rehydration therapy, and hemodialysis resulted in partial remission. Thus, we diagnosed the patient with Evans syndrome presenting with AKI. The patient was successfully treated by the addition of steroid treatment. When AKI presents with hemolysis and thrombocytopenia, physicians should consider Evans syndrome, which can be appropriately treated when detected early.

**Keywords:** Acute kidney injury, Evans syndrome

**Cite this article as:** Lin H, Wu K, Zhang W, Lin G, Cai C. Evans syndrome with acute kidney injury. Arch Iran Med. 2019;22(6):336-339.

Received: June 17, 2018, Accepted: April 16, 2019, ePublished: June 1, 2019

**Introduction**

Evans syndrome, which was first described by Evan and Duane in 1951, is a rare syndrome associated with the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP).<sup>1</sup> In this syndrome, antibodies and/or complement cause lysis of red blood cell membranes, leading to progressive red blood cell damage and hemolytic anemia. Antiplatelet autoantibodies are produced simultaneously; thus, reduced platelet count is observed in patients with AIHA or ITP.<sup>2</sup> Evans syndrome may occur simultaneously with or as a subsequent complication of many diseases, including systemic lupus erythematosus, Hashimoto's thyroiditis, scleroderma, dermatomyositis, rheumatoid arthritis, primary hyperthyroidism, malignant tumors of the blood and lymphatic system, other malignant diseases (e.g., thymoma, some solid tumors), and immunodeficiencies. The primary clinical manifestations of Evans syndrome include anemia, bleeding, jaundice, hepatosplenomegaly, and hemoglobinuria. Furthermore, it is a poor prognostic factor in autoimmune cytopenias.<sup>3,4</sup>

Acute kidney injury (AKI) is a syndrome characterized by the rapid loss of kidney excretory function and is most often secondary to extrarenal events.<sup>5</sup> AKI secondary to Evans syndrome has rarely been recorded. Here, we report a case of Evans syndrome presenting with AKI, which was

successfully treated by steroid administration.

**Case Report**

A 73-year-old woman presented with complaints of diarrhea, vomiting, and increased serum creatinine for 2 days in August 2015, after developing the symptoms of a cold. On that day, she had passed watery stool three times, totaling approximately 1000 g. She had also vomited three times, totaling approximately 200 g, and exhibited tea-colored urine output of approximately 50 mL daily. She had no prior history of fever, cough, abdominal cramps, or urinary irritation symptoms. She was treated in our hospital emergency department. Peripheral blood count and a renal function test showed the following: white blood cell count (WBC) of  $14.27 \times 10^9/L$ , hemoglobin (Hb) of 104 g/L, platelet count (PLT) of  $70 \times 10^9/L$ , and serum creatinine (SCr) of 734  $\mu\text{mol/L}$  (Table 1). She reported a history of AIHA and urticaria 4 years prior. Two years prior, she had exhibited anemia, thrombocytopenia, and renal injury after acute gastroenteritis. She was diagnosed with acute renal injury, acute gastroenteritis, and AIHA in both January 2014 and July 2014 (Table 1).

Physical examination revealed a temperature of 36.5°C, breathing rate of 18 breaths/min, blood pressure of 88/56 mm Hg, and weight of 50 kg. The patient exhibited no eruption or purpura on the skin. Her chest examination was normal. Her heart rate was 95 bpm, regular and

\*Corresponding Author: Chudan Cai, MD; Department of Nephrology Medicine, The first Affiliated Hospital of Shantou University Medical College, Shantou, China. Emails: cdcai@stu.edu.cn, ccd201806@163.com

**Table 1.** The Results of the Auxiliary Examination

Date	2014-01	2014-04	2014-07	2014-09	2015-08-11	2015-08-23	2016-11
<b>Complete blood count</b>							
White blood cells (/L)	13.87×10 <sup>9</sup> ↑	9.49×10 <sup>9</sup>	12.04×10 <sup>9</sup> ↑	8.39×10 <sup>9</sup>	14.27×10 <sup>9</sup> ↑	12.29×10 <sup>9</sup>	6.09×10 <sup>9</sup>
Neutrophils (%)	80.59 ↑	55.87	79.48 ↑	55.06	84.43 ↑	63.96	58.64
Hemoglobin (g/L)	88 ↓	124	109 ↓	97 ↓	104 ↓	91	127
Platelets (/L)	87×10 <sup>9</sup> ↓	340×10 <sup>9</sup>	65×10 <sup>9</sup> ↓	254×10 <sup>9</sup>	70×10 <sup>9</sup> ↓	203	274×10 <sup>9</sup>
<b>Urinalysis</b>							
Occult blood	3+	—	3+	—	3+	—	—
Protein	1+	—	1+	—	-	—	—
Leukocyte	3+	—	2+	—	1+	—	—
<b>Biochemistry</b>							
Albumin (g/L)	31.20 ↓	32.80 ↓	36.00	34.80 ↓	34.60 ↓	34.00	39.00
BUN (mmol/L)	31.88 ↑	9.87 ↑	26.65 ↑	12.13 ↑	23.67 ↑	13.31	5.78
Creatinine (μmol/L)	785 ↑	145 ↑	585 ↑	188 ↑	734 ↑	179 ↑	132
CRP (mg/L)	103 ↑	6	110 ↑	12 ↑	130 ↑	10	5
<b>Immune-serological findings</b>							
Direct Coombs test	Positive	Negative	Positive	Negative	Positive	Negative	Negative

Abbreviations: BUN, blood urea nitrogen; CRP, C-reactive protein; APTT, activated partial thromboplastin; FDP, fibrin fibrinogen degradat. Abnormal values are shown by arrows: ↑, higher than normal range; ↓, lower than normal range.


without murmur. Abdominal examination was normal and there was no edema of the lower limbs. Coagulation, peripheral blood smear, and bone marrow aspirate were normal. Stool culture showed normal intestinal flora. B-ultrasound examination showed no hepatosplenomegaly or retroperitoneal mass; kidneys, ureter, and bladder were normal. Renal pathology was as follows: light microscopy showed no obvious glomerular lesions, proximal tubules exhibited focal loss of brush border staining, and there was diffuse interstitial edema with an interstitial infiltrate of inflammatory cells (Figure 1a). Immunofluorescence staining was negative for fibrinogen, κ, λ, IgG, IgM, IgA, C3, C4, and C1q; Congo Red staining was also negative. Electron microscopy analysis of renal tissues showed that vacuoles were present in glomerular capillary endothelial cells, and red blood cells were evident in glomerular capillary lumens; in renal tubules and interstitia, proximal tubules contained numerous uniform cytoplasmic vacuoles, whereas proximal tubules exhibited focal loss of brush border staining. Further, there was diffuse interstitial edema with an interstitial infiltrate of inflammatory cells (Figure 1b). Renal pathology results suggested a diagnosis of moderate subacute interstitial nephritis.

During prior treatment, the patient had undergone antibiotic therapy, rehydration therapy, and hemodialysis, which resulted in partial remission. In the most recent presentation of disease (August 2015), the patient was considered for Evans syndrome and acute gastroenteritis that developed into AKI. The patient began doses of intravenous methylprednisolone 250 mg for 3 days, followed by oral prednisolone at 60 mg/d, which was

gradually reduced after 2 weeks, combined with rehydration and packed red blood cell transfusion. Over approximately 6 months, the features of AKI improved and there were no signs of hemolysis and thrombocytopenia. The patient's renal function did not return to normal, with creatinine levels between 150 and 180 μmol/L. The patient was then administered oral prednisolone at 10 mg/day for an additional 6 months. Renal function returned to normal at the 1-year follow-up examination.

### Discussion

The patient presented with diarrhea, vomiting, and oliguria with AKI, concurrent with AIHA and thrombocytopenia, resulting in a differential diagnosis of Evans syndrome presenting with AKI. Combined with her past history of AIHA, the patient had diarrhea gastroenteritis, high WBC, and elevated inflammation, based on increased C-reactive protein; she also exhibited reduced blood pressure and dehydration, suggesting intestinal infection. Examination revealed anemia, thrombocytopenia, a positive Coombs test, and elevated SCr. The most likely diagnosis was Evans syndrome and intestinal infection that had developed into AKI. However, with prior antibiotic therapy, rehydration therapy, and hemodialysis, the patient had shown partial remission in April 2014 and September 2014 (Table 1). Thus, intestinal infection was not likely to be the primary cause of AKI. Due to morbidity in this case, steroids were added to the therapeutic protocol to control symptoms of Evans syndrome; the patient's renal function and anemia gradually improved and had returned to normal at 1 year of follow-up. Evans syndrome presenting with AKI is a



**Figure 1.** (a) Light microscopy showed there was diffuse interstitial edema with an interstitial infiltrate of inflammatory cells. (b) Electron microscopy showed that vacuoles were present in glomerular capillary endothelial cells, and red blood cells were evident in glomerular capillary lumens.

rare case to be recorded.

Other differential diagnoses in this case included hemolytic uremic syndrome (HUS)/ITP. Presentation with AKI, hemolytic anemia, and thrombocytopenia as the main symptoms can also be indicative of HUS/ITP. The clinical features of HUS/ITP are hemolytic anemia in microvessels, thrombocytopenia, kidney and central nervous system damage, peripheral blood smears exhibiting broken red blood cells, and a significant increase in blood pressure. However, the patient showed normal peripheral blood erythrocyte fragments and her blood pressure was low, reducing the likelihood of HUS/ITP. Finally, leukemia was a possible diagnosis: elderly women who present with anemia and thrombocytopenia should be checked for the presence of leukemia. However, bone marrow analysis did not support a diagnosis of leukemia.

The precise etiology and pathogenesis of Evans syndrome has not been fully elucidated; Evans syndrome has a chronic course with periods of exacerbation and remission. Our case of a patient with Evans syndrome presents another etiologic avenue: AKI. Bone marrow examination was within normal limits and did not show infiltration of immature lymphoid cells. There were no clinical features of lymphadenopathy; however, diagnostic renal biopsy showed massive lymphocyte infiltration and some immunologic tests were positive, which was consistent with the prior literature regarding Evans syndrome as a disorder of immune regulation. Recent observations have confirmed an increased level of T cell activation and apoptosis, with dramatic reduction in the number of naïve CD4+ T cells and an imbalance of Th1/Th2 responses in Evans syndrome.<sup>6</sup> In acute renal failure, nonspecific immunity and specific acquired immunity, inflammatory factors, T and B lymphocytes play an important role, especially in the balance of Th1/Th2 responses. T lymphocytes have been implicated in a mouse renal ischemia-reperfusion model and play an important role in the resulting injury.<sup>7</sup> The balance of Th1/Th2 responses has been confirmed to play an important role

in renal ischemia-reperfusion injury.<sup>8-10</sup> Therefore, in this case we could not rule out Evans syndrome caused by a reduction in the number of naïve CD4+ T cells and an imbalance in Th1/Th2 responses, which promoted the occurrence of AKI.

In our case, the patient had been previously hospitalized three times: once, she was diagnosed with AIHA, while the other instances resulted in diagnoses of AKI after acute gastroenteritis. With antibiotic therapy, rehydration therapy, and hemodialysis, she experienced partial remission; however, this response was lost upon dose reduction and/or during acute infections,<sup>11</sup> since there was no diagnosis of Evans syndrome and prednisolone was not used. Treatment of Evans syndrome is largely empirical. The first-line therapy for Evans syndrome is usually steroids and/or intravenous immunoglobulins; options for second-line therapy include immunosuppressive drugs, especially mycophenolate mofetil, vincristine, cyclophosphamide, and rituximab.<sup>12,13</sup> A large majority (80%) of Evans syndrome patients respond to corticosteroids. Typically, corticosteroids are administered at an initial dose of 1–4 mg/kg/d.<sup>3</sup> In our case, renal function and anemia gradually improved with prednisolone treatment combined with rehydration, along with blood component support. After 1 year of follow-up, the patient's renal function and routine blood tests were normal and her prognosis continues to be favorable.

A patient with Evans syndrome presenting with AKI is rare. The symptoms of AIHA and ITP meet the strict inclusion criteria for Evans syndrome without secondary factors. Renal function can be gradually restored to normal levels by treatment with steroid hormones and immunosuppressive drugs. This case was presented to illustrate that when AKI presents with hemolysis and thrombocytopenia, physicians should consider Evans syndrome, which can be appropriately treated when detected early.

#### Authors' Contribution

HL and KW conceived and drafted the manuscript. WZ and GL collected and collated data. CC reviewed and finally approved the manuscript.

#### Conflict of Interest Disclosures

The authors have no conflicts of interest.

#### Ethical Statement

The Helsinki Declaration was followed in this study.

#### References

1. Evans RS, Takahashi K, Duane RT, Payne R, LIU C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. *AMA Arch Intern Med.* 1951;87(1):48-65.
2. Norton A, Roberts I. Management of Evans syndrome. *Br J Haematol.* 2006;132(2):125-37.
3. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis

- of 68 cases. *Blood*. 2009;114(15):3167-72. doi: 10.1182/blood-2009-04-215368.
4. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood*. 2014;124(19):2930-6. doi: 10.1182/blood-2014-06-583021.
  5. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. *Lancet*. 2012;380(9843):756-66. doi: 10.1016/S0140-6736(11)61454-2.
  6. Giovannetti A, Pierdominici M, Esposito A, Cagliuso M, Stifano G, Giammarioli AM, et al. Progressive derangement of the T cell compartment in a case of Evans syndrome. *Int Arch Allergy Immunol*. 2008;145(3):258-67.
  7. Noel S, Martina MN, Bandapalle S, Racusen LC, Potteti HR, Hamad AR, et al. T Lymphocyte-Specific Activation of Nrf2 Protects from AKI. *J Am Soc Nephrol*. 2015;26(12):2989-3000. doi: 10.1681/ASN.2014100978.
  8. Ysebaert DK, De Greef KE, De Beuf A, Van Rompay AR, Vercauteren S, Persy VP, et al. T cells as mediators in renal ischemia/reperfusion injury. *Kidney Int*. 2004;66(2):491-6.
  9. Marques VP, Gonçalves GM, Feitoza CQ, Cenedeze MA, Fernandes Bertocchi AP, Damião M, et al. Influence of TH1/TH2 switched immune response on renal ischemia-reperfusion injury. *Nephron Exp Nephrol*. 2006;104(1):e48-56. doi:10.1159/000093676
  10. Frossi B, De Carli M, Piemonte M, Pucillo C. Oxidative microenvironment exerts an opposite regulatory effect on cytokine production by Th1 and Th2 cells. *Mol Immunol*. 2008;45(1):58-64. Doi:10.1016/j.molimm.2007.05.008
  11. Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. *J Pediatr*. 1980;97(5):754-8.
  12. Park CY, Chung CH. A patient with mixed type Evans syndrome: efficacy of rituximab treatment. *J Korean Med Sci*. 2006 Dec;21(6):1115-6.
  13. Norton A, Roberts I. Management of Evans syndrome. *Br J Haematol*. 2006; 132(2):125-137.